ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2261

Risk of Cervical Intraepithelial Neoplasia During Janus Kinase (JAK) Inhibitor Treatment in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Abstract Number: 2262

Window of Opportunity in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease with Abatacept. National Multicenter Study of 526 Patients
Abstract Number: 2263

The Potential Use of Circulating Extracellular Vesicles for Improved Diagnosis and Therapy in Rheumatic Inflammatory/autoimmune Diseases: Proof of Concept Studies
Abstract Number: 2264

The Risk of Malignancy and Major Adverse Cardiovascular Events with the Use of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Real-World Evidence
Abstract Number: 2265

Patient’s Global Assessment of Disease Activity Is the Most Relevant Factor for Near-Miss of Boolean 2.0 Remission in Patients with Rheumatoid Arthritis: Post Hoc Analysis from the Observational UPwArds Study
Abstract Number: 2266

Immunosuppressive Medications and Common Infections in Patients with Rheumatoid Arthritis
Abstract Number: 2267

A Novel Blood-based Assay That Predicts Clinical Response to TNFα Inhibitors or Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis
Abstract Number: 2268

The Discontinuation and Effectiveness of Sequential Advanced Therapy in Rheumatoid Arthritis, a Real-World Data
Abstract Number: 2269

Adalimumab Dose Reduction Using Therapeutic Drug Monitoring to Manage Low Disease Activity in Rheumatoid Arthritis: A Single-Blind, Non-Inferiority, Randomized Clinical Trial
Abstract Number: 2270

Low Yield of Routine Serological Screening for Hepatitis B in Patients with Rheumatoid Arthritis Starting Rituximab Therapy in a Non-Endemic Country
Abstract Number: 2271

Intra-Articular Injection of Human Bone Marrow-Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial
Abstract Number: 2272

Evolution of Methotrexate and Prednisone Use in the Era of Biologic Therapy: 15-Year Findings from a Large Rheumatoid Arthritis Registry
Abstract Number: 2273

Time-Trends in Real-World Glucocorticoid Treatment Strategies in Patients with Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort(CATCH) Study
Abstract Number: 2274

Efficacy and Safety of the Biased Melanocortin Receptor Agonist AP1189/resomelagon in Combination with Methotrexate in DMARD-naïve Rheumatoid Arthritis Patients: The EXPAND Trial
Abstract Number: 2275

Cardiovascular and Cancer Safety of JAKi Compared to TNFi in Patients with Rheumatoid Arthritis: Results from a National Registry of Advanced Therapies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].